

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44172 A1

(51) International Patent Classification⁷: C07C 257/18,
279/18, A61K 31/155, A61P 7/02, 35/00

(21) International Application Number: PCT/US00/34211

(22) International Filing Date:
14 December 2000 (14.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/170,916 15 December 1999 (15.12.1999) US

(71) Applicant (for all designated States except US): AXYS
PHARMACEUTICALS, INC. [US/US]; 180 Kimball
Way, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ALLEN, Darin,
Arthur [US/US]; 855 Mountain View Drive, #8, Daly
City, CA 94014 (US). MCGEE, Danny, Peter, Claude
[CA/US]; 20 S. Grant Street, San Mateo, CA 94401 (US).
SPENCER, Jeffrey, R. [US/US]; 8 Baycrest Way, South
San Francisco, CA 94080 (US).

(74) Agents: KATHARDEKAR, Vinit, G. et al.; Axys Pharmaceuticals, Inc., 180 Kimball Way, South San Francisco, CA 94080 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SALICYLAMIDES AS SERINE PROTEASE INHIBITORS



(I)

(57) Abstract: The present invention provides novel compounds of Formula (I), its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The present invention also provides a process for the selective acylation of an amino group.

WO 01/44172 A1

SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS**FIELD OF INVENTION**

The present invention relates to novel serine protease inhibitors.

5

BACKGROUND OF THE INVENTION

One of the most active areas in cancer research is in the field of proteolytic enzymes and their role in the spread of cancer. One class of proteases that plays a significant role in the progression of cancer are the serine proteases, in particular 10 Urokinase-type plasminogen activator (uPA). Inhibitors of uPA have been postulated to be of therapeutic value in treating cancer. Inhibitors of these serine proteases also tend to be inhibitors of the closely related blood-clotting enzymes. One such blood-clotting enzyme is Factor Xa.

Factor Xa (herein after "FXa"), the converting enzyme of pro-thrombin to 15 thrombin, has emerged as an alternative target (to thrombin) for drug discovery for thromboembolic disorders. A variety of compounds have been developed as potential FXa inhibitors.

Kunitada and Nagahara in Current Pharmaceutical Design, 1996, Vol. 2, No.5, report amidinobenzyl compounds as FXa and thrombin inhibitors. Disclosed 20 in U.S. Patent No. 5,576,343 are aromatic amidine derivatives and salts thereof, as reversible inhibitors of FXa. These compounds comprise amidino substituted indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazoyl, benzothiazolyl, naphthyl, tetrahydronaphthyl and indanyl groups, attached to a substituted phenyl ring by an alkylene group having from 1 to 4 carbon atoms.


In spite of the above discussed efforts, desirable treatment of cancer and thromboembolic disorders still remains elusive. There is thus a need for new compounds that will be effective in inhibiting serine proteases, such as Urokinase, and blood-clotting enzymes such as FXa. Keeping these needs in mind, the present invention provides novel inhibitors as discussed below.

SUMMARY OF THE INVENTION

Keeping the above discussed needs in mind, the present invention provides novel salicylamides of Formula I as serine protease inhibitors. Included in the present invention are pharmaceutically acceptable salts of compounds of Formula I, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of a compound of Formula I, a method of treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, and a method for treating cancer in mammals comprising administering a therapeutically effective amount of a compound of Formula I. Also provided by the present invention is a process for selectively acylating an amino group.

DETAILED DESCRIPTION


Provided by the present invention is a compound of Formula I:




Formula I

its prodrug form or pharmaceutically acceptable salts thereof, wherein:

- 5 R¹ represents OH, COOH, COO-C₁₋₄ alkyl, CH₂OR¹⁰, SO₂-OH, O-SO₂-OC₁₋₄ alkyl, OP(O)(OH)₂, or OPO₃C₁₋₄ alkyl;
- R², R³, R⁴, and R⁵ independently at each occurrence represent H, SH, OR¹⁰, halogen, COOR¹⁰, CONR¹¹R¹², optionally substituted aryl, optionally substituted heterocyclyl, C₄₋₁₄ cycloalkyl-C₁₋₄ alkyl, C₁₋₄ alkyl aryl, optionally substituted C₁₋₁₄ straight chain, branched or cyclo alkyl, NR¹⁰R²⁴, (CH₂)₁₋₄-NR³³R³⁴, (CH₂)₁₋₄-COOR³³, O-(CH₂)₁₋₃-CO-het, O-(CH₂)₁₋₂-NH-CO-aryl, O-(CH₂)₀₋₂-NR¹⁰-CO-NR¹⁰R³³, O-(CH₂)₀₋₂-C(O)-NR³³R³⁴, O-(CH₂)₁₋₄-COOR¹⁰, O-(CH₂)₁₋₃-het-R³², O-optionally substituted cycloalkyl, O-(CH₂)₁₋₄-NR¹⁰-COO-t-butyl, O-(CH₂)₁₋₄-NR¹⁰R³³, O-(CH₂)₁₋₄-NR¹⁰-C(O)-C₀₋₃-alkyl-optionally substituted aryl, O-(CH₂)₀₋₆-optionally substituted aryl, (CH₂)₁₋₄-NH-C(O)O-(CH₂)₁₋₄-PhR¹³R¹⁴, NO₂, O-(CH₂)₀₋₄-C(O)-NH-tetrahydro carboline, SO₃H, CH(OH)COOR¹⁰, NR¹⁰R²⁸, O-(CH₂)₁₋₃-optionally substituted het, CH₂COOCH₃, CH=CH-COOCH₃,



alternatively R² and R³, R³ and R⁴, or R⁴ and R⁵ taken together form




R⁶, R⁹ and R⁵³ independently at each occurrence represents H, halogen, cyano, C₁₋₄

alkyl, C₁₋₄ halogenated alkyl, NO₂, O-aryl or OR¹¹;

alternatively R⁶ and R⁵³ taken together form

10



R⁷ and R⁸ independently at each occurrence represent OH, CF₃, H, COOH, NO₂, C₁₋₄

alkyl, OC₁₋₄ alkyl, or O-aryl, halogen, cyano, or a basic group selected from

guanidino, NH(CH=NH)NH₂, C(=NH)N(R¹⁰)₂, C(=NH)-NH-NH₂, C(=O)N(R¹⁰)₂, 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, C(O)CH₂NH₂, C(O)NHCH₂CN, NHCH₂CN, and thiazolidin-3-yl-methylideneamine; with the proviso that only one of R⁷ and R⁸ represent a basic group;


R¹⁰ independently at each occurrence represents H, (CH₂)₀₋₂-aryl, C₁₋₄ halo alkyl, or C₁₋₁₄ straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R¹⁰ groups, the atom along with the R¹⁰ groups can form a five to 10 membered ring structure;

X₁, X₂, X₃ and X₄ independently at each occurrence represent a carbon or a nitrogen atom;

R¹¹ and R¹² independently at each occurrence represent H or C₁₋₄ alkyl;

R¹³ represents H, OH, OC₁₋₄ alkyl, OAr, OC₅₋₁₀ cycloalkyl, OCH₂CN, O(CH₂)₁₋₂NH₂, OCH₂COOH, OCH₂COO-C₁₋₄ alkyl or

15



R²⁰ represents H or OH;

R²⁴ represents R¹⁰, (CH₂)₁₋₄-optionally substituted aryl, (CH₂)₀₋₄OR¹⁰, CO-(CH₂)₁₋₂-N(R¹⁰)₂, CO(CH₂)₁₋₄-OR¹⁰, (CH₂)₁₋₄-COOR¹⁰, (CH₂)₀₋₄-N(R¹⁰)₂, SO₂R¹⁰, COR¹⁰,

20 CON(R¹⁰)₂, (CH₂)₀₋₄-aryl-COOR¹⁰, (CH₂)₀₋₄-aryl-N(R¹⁰)₂, or (CH₂)₁₋₄-het-aryl;

R^{28} represents $(CH_2)_{1-2}-Ph-O-(CH_2)_{0-2}-het-R^{30}$, $C(O)-het$, $CH_2-Ph-CH_2-het-(R^{30})_{1-3}$;

$(CH_2)_{1-4}-cyclohexyl-R^{31}$, $CH_2-Ph-O-Ph-(R^{30})_{1-2}$, $CH_2-(CH_2OH)-het-R^{30}$, $CH_2-Ph-O-$ cycloalkyl- R^{31} , $CH_2-het-C(O)-CH_2-het-R^{30}$, or $CH_2-Ph-O-(CH_2)-O-het-R^{30}$;


R^{30} represents $SO_2N(R^{10})_2$, H, NHOH, amidino, or $C(=NH)CH_3$;

5 R^{31} represents R^{30} , amino-amidino, $NH-C(=NH)CH_3$ or R^{10} ;

R^{32} represents H, $C(O)-CH_2-NH_2$, or $C(O)-CH(CH(CH_3)_2)-NH_2$;

R^{33} and R^{34} independently at each occurrence represent R^{10} , $(CH_2)_{0-4}-Ar$, optionally substituted aryl, $(CH_2)_{0-4}$ optionally substituted heteroaryl, $(CH_2)_{1-4}-CN$, $(CH_2)_{1-4}-N(R^{10})_2$, $(CH_2)_{1-4}-OH$, $(CH_2)_{1-4}-SO_2-N(R^{10})_2$;

10 alternatively, R^{33} and R^{34} along with the nitrogen atom that they are attached to forms a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-Dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



15

R^{35} represents R^{10} , SO_2-R^{10} , COR^{10} , or $CONHR^{10}$;

E represents a bond, $S(O)_{0-2}$, O or NR^{10} ;

Q, Q^1 , Q^2 , Q^3 , L^1 , L^2 , L^3 and L^4 independently at each occurrence represent N-natural or unnatural amino acid side chain, CHR^{10} , O, NH, $S(O)_{0-2}$, $N-C(O)-NHR^{10}$,

20 $SO_2-N(R^{10})_2$, $N-C(O)-NH-(CH_2)_{1-4}-R^{26}$, NR^{10} , N-heteroaryl, $N-C(=NH)-NHR^{10}$, or $N-C(=NH)C_{1-4}$ alkyl;

R^{26} represents OH, NH₂, or SH;

R^{51} and R^{52} independently represent COOH, CH₂OH, CH₂COOH, COOR, CH₂COOR, alkyl or CO-NH₂; alternatively



R^{51} and R^{52} taken together represent =O, =S, =CH₂ or =NR¹⁰;

5 R^{53} represents H, halogen, cyano, C₁₋₄ alkyl, C₁₋₄ halogenated alkyl, NO₂, O-aryl or OR¹¹;

with the proviso that at least two of X₁, X₂, X₃ and X₄ represent a carbon atom, and when any of X₁, X₂, X₃ and X₄ represent a nitrogen atom the corresponding substituent does not exist.

10 In a preferred embodiment of the present invention is provided a compound of Formula I wherein, R¹ represents OH or COOH; R²⁰ represents H; R⁵¹ and R⁵² taken together form =O; and X₁, X₂, X₃, and X₄ represent C. Another preferred embodiment provides a compound wherein, R² represents halo, H, NH-CO-Ph, *i*-propyl, OH, OCH₃, OC₂H₅, CH(OH)COOH, O-*I*-propyl, SO₃H, NH₂, 15 CH(OH)COOC₁₋₂ alkyl, CH₃, NO₂ or Ph;

R³ represents H, OH, NH₂ OC₁₋₄ alkyl, C₁₋₄ alkyl, NHCH₃, O-(CH₂)₁₋₃-OCO-C₁₋₂ alkyl, NH-C(O)C₁₋₂ alkyl, O-(CH₂)₁₋₂-CO-NH₂, Ph, NHCOCF₃, N=CH-N(CH₃)₂, O-CH₂-CO-NH-(CH₂)₁₋₃-Ph,




20 R⁴ represents H, C₁₋₄ alkyl, halogen, *i*-propyl, OH, NH₂ 3-nitro-phen-1-yl, NH-CO-CH₃, CH₂-NH-(CH₂)₃-Ph, 2,4-difluoro-phen-1-yl, NHCOCF₃, benzo[1,3]dioxol-5-yl,

4-Carbamimidoyl-phenylazo, 3-Hydroxy-4-carboxyl-phenylsulfanyl; 1,3-Dioxo-indan-2-yl, or toluene-4-sulfonylamino;

R⁵ represents H or OH;

alternatively, R² and R³, R³ and R⁴, or R⁴ and R⁵ can be taken together to form

5



R⁶ represents H;

R⁷ represents C(=NH)-NH₂ or NH-C(=NH)-NH₂;

10 R⁸ represents H or halogen; and


R⁹ represents H.

A further preferred embodiment provides a compound wherein, R² represents halo, H, NH-CO-Ph, *i*-propyl, OH, CH₃, or NO₂;

15 R³ represents H, OH, NH₂ OC₁₋₂ alkyl, C₁₋₄ alkyl, O-(CH₂)₁₋₃-OCO-C₁₋₂ alkyl, NH-C(O)CH₃, O-CH₂-CO-NH₂, Ph, NHCOCF₃, N=CH-N(CH₃)₂, O-CH₂-CO-NH-(CH₂)₂-Ph;


R⁴ represents H, CH₃, methoxy, halogen, *i*-propyl, 3-nitro-phen-1-yl, NHCOCF₃, benzo[1,3]dioxol-5-yl, NHCOCH₃, 4-Carbamimidoyl-phenylazo, 3-Hydroxy-4-carboxyl-phenylsulfanyl or 1,3-Dioxo-indan-2-yl;

20 alternatively, R² and R³, R³ and R⁴, or R⁴ and R⁵ can be taken together to form



R^{13} represents C_{1-2} alkyl, OH, $O(CH_2)_{1-2}-NH_2$, H, or

5



Particularly preferred compounds of the present invention are:

- N-(4-Carbamimidoyl-phenyl)-2-hydroxy-3-iodo-5-methyl-benzamide;
- 3,5-Dibromo-N-(4-carbamimidoyl-phenyl)-2,4-dihydroxy-benzamide;
- 5-Bromo-N-(4-carbamimidoyl-phenyl)-2,4-dihydroxy-3-iodo-benzamide;
- 10 3-Hydroxy-naphthalene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide; and
- 3-Hydroxy-7-methoxy-naphthalene-2-carboxylic acid (4-guanidino-phenyl)-amide.

Another aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of (i) a compound; or (ii) a pharmaceutically acceptable salt of a compound of Formula I. Also provided by the present invention is a method of treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.



In yet another aspect of the present invention is provided a process for selectively acylating an amino group, said process comprising treating a molecule comprising an amino group with an acylating agent in the presence of an acetamide to yield a compound with an acylated amino group. A preferred embodiment 5 provides a process wherein the amino group is selectively acylated in the presence of another acylatable group. Yet another preferred embodiment provides a process wherein the acylatable group is selected from an optionally substituted amino ketone, alkyl amidino, alkyl guanidino, C(=NH)NH-NH₂, aryl-(CH₂)₀₋₄-NHR¹⁰, amidino and guanidino; the acylating agent comprises an acid halide group; and wherein the 10 acetamide is an alkyl or dialkyl acetamide.

A further preferred embodiment provides a process wherein the acetamide is selected from a group consisting of DMA, diethyl acetamide, dimethyl propionamide, diethyl propionamide and N-methylpyrrolidinone; the process is carried out at a temperature ranging from about 25°C to about 50°C; and wherein the 15 acylating agent is a protected salicylic acid chloride selected from acetic acid 2-chlorocarbonyl-phenyl ester and 2-benzyloxy-benzoyl chloride.

EXPERIMENTAL

Novel compounds of the present invention can be prepared by the synthetic 20 schemes outlined below:

SCHEME-I



5 STEP-1

A mixture of a compound of Formula A (1 eq.), a compound of Formula B (1.2 eq.) and dimethyl acetamide (DMA) is stirred at ambient temperature from about 30 minutes to about 2 hours, or until a TLC analysis indicates absence of the compound of Formula A. The reaction mixture then is diluted with ether or water leading to the 10 formation of a precipitate of a compound of Formula I. This precipitate is isolated and dried. Structural confirmation and compound identification is accomplished by techniques such as proton NMR (¹H NMR), mass spectral analysis (MS) and elemental analysis.

15 Formula I (R¹ = OH)

Conversion of Formula I compounds, where R¹ is O-acetyl, to Formula I compounds, where R¹ is OH, is accomplished by treating a compound of Formula I with a base, preferably aqueous ammonium hydroxide. The reaction mixture is initially clear but formation of a yellowish precipitate indicates the conversion of an 5 O-acetyl group to a hydroxy group. This conversion is generally quantitative. The precipitate is isolated and dried to yield the corresponding compound of Formula I, where R¹ is OH.


Acid Salts

10 Acid salts of compound of Formula I can be formed by stirring a compound of Formula I, having at least one amino center, with an acid, preferably a mineral acid such as HCl. This affords the corresponding acid salt of a compound of Formula I as a solid. The solid is isolated and dried. Structural identification is accomplished using techniques such as (¹H NMR), MS and elemental analysis.

15 Synthesis of Starting Materials

Some of the compounds of Formula A and Formula B can be purchased from commercial sources such as Aldrich Chemicals and Lancaster. Compounds of Formula A and Formula B can also be prepared by synthetic methods known to one skilled in the art. Thus compounds of Formula B can be synthesized as described 20 below.

Synthesis of Compounds of Formula B:





Formula B



Compounds of Formula B are acid chlorides which can be synthesized by dissolving an appropriate carboxylic acid in an appropriate solvent, for example ethyl acetate (EtOAc) with a catalytic amount of DMF, and treating this mixture with about 5 1.5 equivalents of oxalyl chloride. The resulting reaction mixture is stirred at ambient temperature for about 30 minutes. The solvent is evaporated to obtain a compound of Formula B. These compounds of Formula B can be used without further purification.

The acetylated carboxylic acid used above can, in turn, be prepared by acetylating the corresponding hydroxy carboxylic acid, e.g., salicylic acid. The 10 procedure comprises combining a suspension of the hydroxy carboxylic acid in acetic anhydride with catalytic amount of acid, e.g., sulfuric acid and agitating this mixture from about 1 to about 3 hours at ambient temperature. The acetylated carboxylic acid falls out of the solution as a solid. This acetylated carboxylic acid then is used as described above.

15 Scheme II



5

**Formula I**

STEP-(i)

A compound of Formula X (500 mg, 2.5 mmol) was mixed with DMF (5 ml) and 60% sodiumhydroxide (0.32 g) to form a mixture. The mixture then was stirred for about 30 minutes. The stirred mixture was combined with chloroacetonitrile (0.17 ml, 1.1 eq.) and the new reaction mixture was stirred for about 1 hour followed by dilution with 1N HCl to form a precipitate. The precipitate was isolated and dried to yield a compound of Formula Y.

STEP-(ii)


Compounds of Formula B are acid chlorides which can be synthesized by dissolving an appropriate corresponding carboxylic acid in an appropriate solvent, for example ethyl acetate (EtOAc) with a catalytic amount of DMF, and treating this mixture with about 1.5 equivalents of oxalyl chloride. The resulting reaction mixture is stirred at ambient temperature for about 30 minutes. The solvent is evaporated to obtain a compound of Formula B. These compounds of Formula B can be used without further purification.

STEP-1

A mixture of a compound of Formula A (1 eq.), a compound of Formula B (1.2 eq.) and dimethyl acetamide (DMA) was stirred at ambient temperature from about 30 minutes to about 2 hours, or until a TLC analysis indicates absence of the compound of Formula A. The reaction mixture then was diluted with ether or water leading to the formation of a precipitate of a compound of Formula I. This precipitate was isolated and dried. Structural confirmation and compound identification was accomplished by techniques such as proton NMR (^1H NMR), mass spectral analysis (MS) and elemental analysis.

STEP-(iii)

A compound of Formula I (Ex. 168) was combined with a mixture of methanol and 1N HCl followed. The resulting mixture was further combined with Platinum oxide and this mixture was agitated under hydrogen at 35 PSI for about 1 hour. The agitated mixture was filtered and concentrated to yield an oily substance. The oily substance was purified by preparative HPLC eluting with a gradient of 10-90% solvent A in solvent B (The solvent A was 20 mm HCl, solvent B was acetonitrile) to yield a compound of Formula I (Ex. 175).

10 Compounds of Formula I wherein $R^2 = SO_3H$ 

Formula I

A compound of Formula I ($R^2 = H$) (100 mg, 0.31 mmol) was dissolved in concentrated sulfuric acid (2 ml) and then mixed with a sulfur trioxide-N,N-dimethylformamide complex (120 mg, 0.78 mmol). The resulting solution was heated 15 at about 50 °C for about 10 minutes, and then diluted with water to yield a precipitate. The precipitate was isolated and dried to yield a compound of Formula I wherein $R^2 = SO_3H$ (Ex.173) .


Synthesis of Compounds wherein $R^2 = OH$ or NH_2 .

A compound of Formula I ($R^2 = H$) (120 mg, 0.37 mmol) was suspended in water (6 ml) and the suspension was treated with fuming nitric acid (0.5 mL). The resulting mixture was stirred from about 8 to about 16 hours and the solids were isolated by filtration. The solids then were dissolved in a mixture of methanol (10 mL) and 1N HCl (1 mL), the solution was combined with Palladium(II)hydroxide catalyst (20%) and the resulting reaction mixture was agitated in an atmosphere of hydrogen for about 12 hours. The agitated reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to yield a residue. The residue was purified and the two components of the residue were separated using reverse phase HPLC to yield two compounds of Formula I wherein $R^2 = OH$ and NH_2 respectively.

Examples

Listed in TABLES-I, II and III are compounds which were synthesized using the procedures discussed above.



TABLE-I



5 R⁸ and R⁵³ represent H, unless noted otherwise.

Ex.	R ²	R ³	R ⁴	R ⁵	
1	I	H	CH ₃	H	
2	Br	OH	Br	H	
3	I	OH	Br	H	
4	I	NH ₂	I	H	
5	Br	H	CH ₃	H	
6	Br	NH ₂	Br	H	
7	I	H	CH ₃	H	R ⁸ = F
8	I	H	F	H	


Ex.	R ²	R ³	R ⁴	R ⁵	
9	Br	OH	H	H	
10	H			H	
11	H			H	
12	I	H	Cl	H	
13	H			H	
14	Br	H	F	H	
15	Cl	H	H	H	
16	H	OC ₂ H ₅	H	H	
17	Br	OCH ₃	Br	H	
18	H	NH ₂	H	H	
19	H	CH ₃	H	H	
20			H	H	
21	Br	H	Br	H	

Ex.	R ²	R ³	R ⁴	R ⁵	
22	H	OCH ₂ CH ₂ O C(O)CH ₃	H	H	
23	Br	CH ₃	Br	H	
24	CH(CH ₃) ₂	H	CH(CH ₃) ₂	H	
25	OH	H	H	H	
26	H	H	H	OH	
27	CH ₃	H	H	H	
28	Cl	H	Cl	H	
29	Br	H	benzo[1,3]di oxol-5-yl	H	
30	NO ₂	H	NHC(O)CF ₃	H	
31	CH(CH ₃) ₂	H	H	H	
32	H			H	
33	H			H	R ⁸ = F
34	H	OCH ₃	H	H	
35	H	NHC(O)CH ₃	H	H	

Ex.	R ²	R ³	R ⁴	R ⁵	
36	H	H	NH ₂	H	
37	H	H	CH ₃	H	
38	H	H	H	H	
39	H	OCH ₂ C(O)NH ₂	H	H	
40	H	H	OCH ₃	H	
41	H	OH	H	H	
42	H	NHC(O)CF ₃	H	H	
43	H	OH	H	OH	
44	H	N=CH-N(CH ₃) ₂	H	H	
45	H	H	I	H	
46	H	(3-phenyl-propylcarbamoyl)-methoxy	H	H	
47	Br	H	3-nitro-phenyl	H	
48	H	H	4-carbamimido-yl-phenylazo	H	

Ex.	R ²	R ³	R ⁴	R ⁵	
49	H	OH	Br	H	
50	H	phenethylcarbamoyl-methoxy	H	H	
51	H	H	NHC(O)CH ₃	H	
52	H	benzylcarbamoyl-methoxy	H	H	
53	H	Cl	H	H	
54	H	H	(3-phenylpropylamino)-methyl	H	
55	H	H	F	H	
56	H	H	2,4-difluorophenyl-1-yl	H	
57	H	H	3-(4-carbamimidoyl-phenylcarbamoyl)-4-hydroxy-phenylsulfanyl	H	
58	H	(2-morpholin-4-yl-ethylcarbamoyl)-methoxy	H	H	
59	H	H	Cl	H	
60	H	H	Br	H	
61	H	H	benzo[1,3]dioxol-5-yl	H	

Ex.	R ²	R ³	R ⁴	R ⁵	
62	H	[tetrahydro-furan-2-ylmethyl)-carbamoyl]-methoxy	H	H	
63			OH	H	
64	H	H	2-carboxy-4-mercaptopyl-phenol	H	
65	Ph	H	H	H	
66	H	H	H	H	R ⁵³ = CH ₃
67	H	H	1,3-dioxo-1,3-dihydroisoindol-2-yl	H	
68	H	H	NHC(O)CF ₃	H	
69	H	H	toluene-4-sulfonylamino	H	
70	H	H	3-nitrophen-1-yl	H	
71	I	H	CH ₃	H	R ⁸ = F
72	H	O(CH ₂) ₅ COOC ₂ H ₅	H	H	
73	H	O(CH ₂) ₅ COOH	H	H	
74	NH ₂	H	H	H	

Ex.	R ²	R ³	R ⁴	R ⁵	
75	H			H	
76	4-cyano-benzoylamino	H	H	H	
77	NHC(O)-Ph	H	H	H	
78	H	OCH ₂ Ph	H	H	
79	H	4-ethoxy-carbonyl-cyclohexyloxy	H	H	
80	I	H	CH ₃	H	R ⁵³ = Cl
81	H	4-Carbamimidoyl-phenyl carbamoyl	OH	H	

Listed below is the proton NMR (^1H NMR) and Mass spectral data for compounds listed in TABLE-I.

Ex. 1.

^1H NMR (DMSO- d_6) δ : 12.42 (s, 1H), 10.91 (s, 1H), 9.33 (s, 2H), 9.02 (s, 2H), 7.98-5 7.85 (m, 6H), 2.30 (s, 3H)

Mass Spec (M+1) = 396

Ex. 2

^1H NMR (DMSO- d_6) δ : 10.8(br, 2H), 9.3(br s, 2H), 8.9(br s, 2H), 8.4(s, 1H), 7.85(m, 4H)

10 Mass Spec (M+1) = 429.6

Ex. 4

^1H NMR (DMSO- d_6) δ : 9.28 (s, 2H), 8.94 (s, 2H), 8.50 (s, 1H), 7.92 (d, 2H, J = 8.91), 7.85 (d, 2H, J = 8.91), 5.90 (s, 2H).

Ex. 5

15 ^1H NMR (DMSO- d_6) δ 12.11 (s, 1H), 10.92 (s, 1H), 9.31 (s, 2H), 9.03 (s, 2H), 7.97-7.85 (m, 5H), 7.66 (s, 1H), 2.30 (s, 3H).

Mass Spec (M+1) = 347.7

Ex. 6

20 ^1H NMR (DMSO- d_6) δ 10.60 (s, 1H), 9.28 (s, 2H), 8.97 (s, 2H), 8.38 (s, 1H), 7.93 (d, 2H, J = 8.91), 7.85 (d, 2H, J = 8.66).

Ex. 8

^1H NMR (DMSO- d_6) δ 9.31 (s, 2H), 8.98 (s, 2H), 8.07 (d, 1H, J = 9.65), 7.99-7.91 (m, 3H), 7.85 (d, 2H, J = 8.66).

Mass Spec (M+1) = 399.7

Ex. 10

¹H NMR (DMSO-d₆) δ: 9.2(br), 8.25(s, 1H), 7.85(br s, 4H), 7.31(d, 1H, J=9 Hz), 7.06(d, 1H, J=2.2 Hz), 6.87(dd, 1H, J=2.5, 8.8 Hz), 6.74(s, 1H), 3.78(s, 3H)

5 Mass Spec (M+1) = 336.6

Ex. 11

¹H NMR (DMSO-d₆) δ: 8.28(m, 1H), 8.16(m, 1H), 7.90(m, 2H), 7.83(m, 2H), 7.5(m, 2H), 6.96(m, 2H), 6.74(s, 1H)

10 Mass Spec (M+1) = 321.9

Ex. 12

¹H-NMR (DMSO-d₆) δ: 11.87 (s, 1H), 10.42 (s, 1H), 9.81 (s, 1H), 7.89 (d, 1H, J = 7.97 Hz), 7.78 (d, 2 H, J = 8.09 Hz), 7.43 (s, 3 H), 7.22 (d, 2H, J = 8.56 Hz), 6.80-6.70
15 (m, 2H), 2.28 (s, 3H).

Mass Spec (M+1) = 284.9

Ex. 13

¹H NMR (DMSO-d₆) δ: 11.2(br s, 1H), 10.95(br s, 1H), 9.3(br s, 2H), 9.0(br s, 2H),
20 8.45(s, 1H), 8.05-7.9(m, 5H), 7.8(d, 1H), 7.55(t, 1H), 7.35(m, 2H)

Mass Spec (M+1) = 306.3

Ex. 14

¹H NMR (DMSO-*d*₆) δ 10.96 (s, 1H), 9.31 (s, 2H), 8.98 (s, 2H), 8.03 (d, 1H, J = 8.66), 7.95 (d, 2H, J = 8.42), 7.88-7.85 (m, 3H).

Mass Spec (M+1) = 353.6

5

Ex. 15

¹H NMR (DMSO-*d*₆) δ 7.89 (d, 2H, J = 8.91 Hz), 7.79 (d, 2H, J = 8.91 Hz), 7.65 (dd, 1H, J = 1.98, 7.92 Hz), 7.19 (dd, 1H, J = 1.98, 7.43 Hz), 6.11 (t, 1H, J = 7.67 Hz).

Mass Spec (M+1) = 289.7

10

Ex. 16

¹H NMR (DMSO-*d*₆) δ 12.08 (s, 1H), 10.56 (s, 1H), 9.27 (s, 2H), 8.95 (s, 2H), 7.99 (d, 2H, J = 8.97 Hz), 7.94 (s, 1H), 7.85 (d, 2H, J = 8.97 Hz), 6.59-6.53 (m, 2H), 4.07 (q, 2H, J = 6.86 Hz), 1.43 (t, 3H, J = 6.86 Hz).

Mass Spec (M+1) = 299.9

15

Ex. 17

¹H NMR (DMSO-*d*₆) δ 10.30 (s, 1H), 9.23 (s, 2H), 8.91 (s, 2H), 7.92 (d, 2H, J = 8.42 Hz), 7.83-7.74 (m, 3H), 6.19 (d, 1H, J = 8.91 Hz), 6.10 (s, 1H).

Mass Spec (M+1) = 270.7

20

Ex. 18

¹H NMR (DMSO-*d*₆) δ 9.31 (s, 2H), 8.98 (s, 2H), 8.47 (s, 1H), 7.95-7.86 (m, 4H), 3.86 (s, 3H).

Mass Spec (M+1) = 443.8

Ex. 19

¹H NMR (DMSO-d₆) δ : 11.7(br s, 1H), 10.65(br s, 1H), 9.4(br s, 2H), 9.05(br s, 2H), 7.9(m, 5H), 6.8(m, 2H), 2.3(s, 3H).

5

Ex. 23

¹H NMR (DMSO-d₆) δ: 12.8(br s, 1H), 11.05(s, 1H), 9.3(br s, 2H), 9.08(br s, 2H), 8.4(d, 1H, J=2.2 Hz), 7.89(m, 4H), 3.55(s, 3H)

Mass Spec (M+1) = 427.6

Ex. 30

10 ¹H NMR (DMSO-d₆) δ: 11.6(br s, 1H), 11.5(br s, 1H), 9.3(br s, 2H), 8.9(br s, 2H), 8.5(s, 1H), 8.3(s, 1H), 7.9(m, 4H)

Mass Spec (M+1) = 411.8

Ex. 32

15 ¹H NMR (DMSO-d₆) δ: 9.2(br, 4H), 8.26(d, 1H, J=3.3 Hz), 7.87(br s, 4H), 7.11(d, 1H, J=3.2 Hz), 7.02(d, 1H, J=3 Hz), 6.73(m, 1H), 6.60(m, 1H)

Mass Spec (M+1) = 321.9

Ex. 36

¹H NMR (DMSO-d₆) δ: 10.75(s, 1H), 10.25(br, 3H), 9.35(br s, 2H), 9.05(br s, 2H), 7.95(m, 4H), 7.85(d, 1H), 7.45(d, 1H), 7.2(d, 1H)

20 Mass Spec (M+1) = 270.8

Ex. 38

N-(4-carbamimidoyl-phenyl)-2-hydroxy-benzamide

A solution of 4-aminoboronitrile (1 g; 7.57 mmol) in THF (25 mL) was combined with acetylsalicyloyl chloride (11.5 g; 1 eq.) and Et₃N (2 mL). This mixture

was agitated for 8-12 hours and then diluted with ethyl acetate (50 mL). The diluted mixture was washed in succession with 1M HCl solution (15 mL), brine (50 mL), dried ($MgSO_4$) and concentrated under reduced pressure to yield a yellow colored oily residue . Purification of the oily residue by flash chromatography yielded 4-(2-acetoxybenzamido)-benzonitrile (0.9g).

The above 4-(2-acetoxybenzamido)-benzonitrile (0.9 g) was dissolved in a 1:3 mixture of dioxane:ethyl acetate (15 mL) and the resulting mixture was cooled to a temperature of from about 0°C to about 15°C. The cold reaction mixture was saturated with gaseous HCl, the reaction vessel was sealed and the reaction mixture was agitated from about 8 to about 12 hours. The reaction mixture was concentrated under reduced pressure to yield a solid. This solid was dissolved in a 2M ammonia solution in ethanol and the resulting mixture was agitated in a sealed reaction vessel from about 8 to about 16 hours. The reaction mixture was concentrated under reduced pressure to yield an oily residue. The oily residue was purified using purification techniques known to one skilled in the art, for example HPLC, to yield N-(4-Carbamimidoyl-phenyl)-2-hydroxy-benzamide (27 mg).

¹H NMR (DMSO-*d*₆) δ: 11.58(br S, 1H), 10.75(br S, 1H), 9.26(br S, 2H), 8.94(br S, 2H), 7.93(dd, 2H, J=8.8, 1.8 Hz), 7.89(dd, 1H, J=6.1,4 Hz), 7.82(dd, 2H, J=9, 2.1 Hz), 7.41(m, 1H), 7.01(d, 1H, J=8 Hz), 6.95(m, 1H).

Mass Spec (M+1) = 255.9

Ex. 39

¹H NMR (DMSO-*d*₆) δ: 12.1(s, 1H), 10.6(s, 1H), 9.3(br s, 2H), 9.1(br s, 2H), 8.0(m, 3H), 7.85(m, 2H), 7.65(br s, 1H), 7.4(br s, 1H), 6.6(m, 2H).

Mass Spec (M+1) = 329.3

Ex. 41

¹H NMR (DMSO-d₆) δ: 11.95(br s, 1H), 10.5(br s, 1H), 10.35(br s, 1H), 9.25(br s, 2H), 8.9(br s, 2H), 7.9(m, 5H), 6.4(m, 2H).

Mass Spec (M+1) = 271.7

5

Ex. 45

¹H NMR (DMSO-d₆) δ: 11.65(br, 1H), 10.7(s, 1H), 9.3(br s, 2H), 9.0(br s, 2H), 8.15(s, 1H), 7.95(d, 2H), 7.85(d, 2H), 7.7(d, 1H), 6.9(d, 1H)

Mass Spec (M+1) = 382.1

Ex. 49

10 ¹H NMR (DMSO-d₆) δ: 12.05(br s, 1H), 11.3(br s, 1H), 10.5(s, 1H), 9.3(br s, 2H), 9.0(br s, 2H), 8.2(s, 1H), 7.9(m, 4H), 6.7(s, 1H).

Ex. 63

15 ¹H NMR (DMSO-d₆) δ: 9.0(br, 4H), 8.28(d, 1H), 7.89(m, 2H), 7.78(m, 3H), 7.33(m, 1H), 7.18(m, 1H).

Mass Spec (M+1) = 322.3

Ex. 65

¹H NMR (DMSO-d₆) δ: 12.45(s, 1H), 10.9(s, 1H), 9.3(s, 2H), 8.95(s, 2H), 8.1(d, 1H), 7.95(d, 2H), 7.55(m, 3H), 7.4(m, 3H), 7.1(t, 1H).

20 Mass Spec (M+1) = 331.9


Ex. 68

¹H NMR (DMSO-d₆) δ: 11.5(br s, 1H), 11.25(s, 1H), 10.7(s, 1H), 9.3(br s, 2H), 8.9(br s, 2H), 8.15(d, 1H), 8.0(d, 2H), 7.9(d, 2H), 7.65(d, 1H), 7.1(d, 1H).

Mass Spec (M+1) = 366.8

Listed in TABLE-II below are compounds wherein R⁷ is a guanidinyl group (NH-C(=NH)NH₂).





5 TABLE-II



Ex.	R ²	R ³	R ⁴	R ⁵	
150	H			H	
151	H			H	
152	Br			H	
153	Br			H	

Ex.	R ²	R ³	R ⁴	R ⁵	
154	H			H	
155	Cl			H	
156	H			H	
157	I			H	
158	H	Ph	H	H	
159	H			H	
160	H	CH ₃	H	H	
161	H			H	R ⁶ = F
162	Br	H		CH ₃	H
163	I	H		CH ₃	H
164	H	OC ₂ H ₅		H	H
165	I	OH		Br	H

Ex.	R ²	R ³	R ⁴	R ⁵	
166	Br	H	Br	H	
167	H		H	H	
168	H		H	H	
169	H		H	H	
170	NH ₂		H	H	
171	OH		H	H	
172	H		H	H	

Ex.	R ²	R ³	R ⁴	R ⁵	
173	SO ₃ H		H	H	
174	H		H	H	
175	H		H	H	
176	H		H	H	

Listed below is the proton NMR (^1H NMR) and Mass spectral data for compounds listed in TABLE-II.

EX. 150

3-Acetoxy-2-naphthoic acid:

5 A mixture of 3-hydroxy-2-naphthoic acid (1 g, 5.3 mmol) and acetic anhydride (1 mL) was combined with con. sulfuric acid (2 drops) resulting in a solidified mixture in about 30 minutes. The solid was washed with acetic acid (15 mL) and recrystallized using a 1:1 mixture of methanol:water to yield 3-Acetoxy-2-naphthoic acid (0.68 g; 56% yield) in the form of yellow needles.

10 $^1\text{H-NMR}$ (DMSO- d_6) δ : 8.60 (s, 1H), 8.11 (d, 1H, J = 8.1 Hz), 7.95 (d, 1H, J = 8.1 Hz), 7.71 (s, 1H), 7.66 (t, 1H, J = 7.0 Hz), 7.58 (t, 1H, 7.5 Hz), 2.30 (s, 3H).

N-(3-hydroxy-2-naphthoyl)-4-aminophenyl guanidine hydrochloride:

A suspension/mixture of 3-acetoxy-2-naphthoic acid (2.0 g, 8.7 mmol), ethyl acetate (17 mL) and catalytic amount of DMF (0.2 mL) was combined with oxalyl chloride (1.1 mL, 13 mmol) to form a mixture. The mixture was agitated for an hour. The agitated mixture was concentrated under reduced pressure to yield 3-acetoxy-2-naphthoyl chloride as a yellowish solid. The preceding naphthoyl chloride and 4-aminophenylguanidine hydrochloride (1.94 g, 8.7 mmol) was suspended in N,N-dimethyl acetamide (DMA). This suspension was agitated for about 8 to 16 hours to form a solution. The solution was diluted with ether (150 mL) and the diluted reaction mixture was agitated vigorously for about 5 minutes forming a precipitate. The precipitate was isolated and dried to yield N-(3-acetoxy-2-naphthoyl)-4-aminophenyl guanidine.

An aqueous mixture of the preceding N-(3-acetoxy-2-naphthoyl)-4-aminophenyl guanidine hydrochloride was treated with 2N NaOH (18 mL, 36 mmol) at a temperature of about 70°C for about 8 hours. Conversion of the acetoxy group to a hydroxy group was confirmed by MS (CI) analysis. The reaction mixture then was 5 acidified with 6M HCl leading to the formation of a golden-yellow colored precipitate. This precipitate was isolated, washed with water and dried to yield N-(3-hydroxy-2-naphthoyl)-4-aminophenyl guanidine hydrochloride (2.75 g). This guanidine hydrochloride was purified by flash chromatography.

The purified N-(3-hydroxy-2-naphthoyl)-4-aminophenyl guanidine hydrochloride was dissolved in aqueous dilute NaOH. This NaOH solution was acidified to a pH of about 6-7 using 6 M HCl leading to precipitate formation. The precipitate was isolated and dried to yield N-(3-hydroxy-2-naphthoyl)-4-aminophenyl guanidine hydrochloride as a tan colored solid (1.36 g; 44% yield).

¹H NMR (DMSO-d₆) δ : 11.33 (3, 1H), 10.71 (s, 1H), 9.84 (s, 1H), 8.49 (s, 1H), 15 7.92 (d, 1H, J = 8.2 Hz), 7.8 (s, 1H, J = 8.5 Hz), 7.75 (d, 1H, J = 8.3 Hz), 7.55-7.30 (m, 7H), 7.25 (d, 2H, J = 8.6 Hz).

Mass Spec (M+1) = 321.0

Ex. 152

¹H-NMR (DMSO-d₆) δ: 11.1 (s, 1H), 9.8 (s, 1H), 8.7 (s, 1H), 8.1 (d, 1H), 8.0 (d, 1H), 20 7.8 (d, 2H), 7.7 (t, 1H), 7.5-7.3 (m, 4H), 7.2 (d, 2H).

Mass Spec (M+1) = 400.7

Ex. 155

¹H-NMR (DMSO-d₆) δ: 11.9 (br s, 1H), 10.9 (s, 1H), 9.7 (s, 1H), 8.6 (s, 1H), 8.0 (d, 1H), 7.9 (d, 1H), 7.7 (d, 2H), 7.6 (t, 1H), 7.5-7.3 (m, 4 H), 7.2 (d, 2H).

Mass Spec (M+1) = 354.8

Ex. 157

5 $^1\text{H-NMR}$ (DMSO- d_6) δ : 12.73 (s, 1H), 11.15 (s, 1H), 9.93 (s, 1H), 8.90 (s, 1H), 8.00
= 7.66 Hz), 7.60-7.45 (m, 4H), 7.29 (d, 2H, J = 8.65 Hz).

Mass Spec (M+1) = 446.9

Ex. 159

10 $^1\text{H-NMR}$ (DMSO- d_6) δ : 11.30 (s, 1H), 10.75 (s, 1H), 10.00 (s, 1H), 8.47 (s, 1H), 7.93
(d, 1H, J = 8.18 Hz), 7.79 (s, 1H), 7.77 (d, 1H, J = 8.52 Hz), 7.65 (d, 1H, J = 8.52 Hz),
7.58-7.32 (m, 7H), 7.01 (d, 1H, J = 8.18 Hz).

Mass Spec (M+1) = 320.9

15

Ex. 160

$^1\text{H-NMR}$ (DMSO- d_6) δ : 11.87 (s, 1H), 10.42 (s, 1H), 9.81 (s, 1H), 7.89 (d, 1H, J =
7.97 Hz), 7.78 (d, 2 H, J = 8.09 Hz), 7.43 (s, 3 H), 7.22 (d, 2H, J = 8.56 Hz), 6.80-6.70
(m, 2H), 2.28 (s, 3H). Mass Spec (M+1) = 284.9.

20

Ex. 162

$^1\text{H NMR}$ (DMSO- d_6) δ : 12.60 (s, 1H), 10.73 (s, 1H), 9.94 (s, 1H), 7.79-7.94 (m, 2H),
7.79 (d, 2H, 8.91), 7.65 (s, 1H), 7.50 (s, 2H), 7.27 (d, 2H, J = 8.66), 2.30 (s, 3H).

Mass Spec (M+1) = 364.8

Ex. 163

¹H NMR (DMSO-d₆) δ: 12.83 (s, 1H), 10.71 (s, 1H), 9.89 (s, 1H), 7.98 (s, 1H), 7.84 (s, 1H), 7.78 (d, 2H, J = 8.91), 7.48 (s, 2H), 7.27 (d, 2H, J = 8.91), 2.29 (s, 3H).

Mass Spec (M+1) = 410.8

5

Ex. 164

¹H NMR (DMSO-d₆) δ: 12.33 (s, 1H), 10.33 (s, 1H), 9.75 (s, 1H), 7.99 (d, 1H, J = 8.71), 7.78 (d, 2H, J = 8.71), 7.40 (s, 2H), 7.23 (d, 2H, J = 8.71), 6.55 (dd, 1H, J = 8.71, 2.38), 6.49 (d, 1H, J = 2.38), 4.07 (q, 2H, J = 6.86 Hz), 1.43 (t, 3H, J = 6.86 Hz).

Mass Spec (M+1) = 314.8.

10

Ex. 167

¹H-NMR (d₆-DMSO) δ (ppm): 11.07 (s, 1H), 11.01 (br s, 1H), 10.73 (s, 1H), 8.73 (s, 1H), 8.32 (s, 1H), 8.23-8.08 (m, 4 H), 7.69 (d, 1H, J = 8.8 Hz), 7.29 (s, 2H), 7.20 (d, 1H, J = 8.8 Hz), 7.10 (d, 1H, J = 8.8 Hz), 4.90 (s, 2H), 3.60-3.44 (m, 8 H).

15 MS (ES) calc. 464.5, found 465.2 (MH⁺).

This compound was prepared by the following process:

3,7-Dihydroxy-naphthalene-2-carboxylic acid benzyl ester

A mixture of 3,7-dihydroxy-naphthalene-2-carboxylic acid (10.0 g, 49 mmol) 20 and NaHCO₃ (10.3 g, 123 mmol) in 70 mL of N,N-dimethylformamide was agitated for approximately 12 hours at ambient temperature and at about 70°C for an additional 4 hours. The mixture was cooled to about 40°C and then combined with benzyl bromide (7 mL, 59 mmol). The resulting mixture was agitated at about 70°C for about 12 hours. The preceding agitated reaction mixture was concentrated under reduced

pressure, diluted with AcOEt and the diluted mixture was sequentially washed with satd. NaHCO₃, satd. NaCl, 0.5 M HCl, and satd. NaCl, dried (Na₂SO₄) and concentrated under reduced pressure to afford a brown oil. The brown oil was diluted with hexanes to form a precipitate which was isolated to afford the benzyl ester as a 5 golden powder (11.65 g, 81%). ¹H-NMR (d₆-DMSO) δ (ppm): 9.95 (s, 1H), 9.62 (s, 1H), 8.23 (s, 1H), 7.60 (d, 1H, J = 8.8 Hz), 7.50 (d, 2H, J = 7.3 Hz), 7.43-7.34 (m, 3 H), 7.22 (s, 1H), 7.13-7.09 (m, 2H), 5.40 (s, 2H).

3-Hydroxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid benzyl ester A mixture of morpholine (2.16 mL, 25 mmol) and anhydrous ether (30 mL) was cooled (-10°C) and treated drop wise with a solution of bromoacetyl bromide (5.0 g, 25 mmol) in ether (20 mL). Triethyl amine (3.5 mL, 25 mmol) then was added drop wise to the reaction mixture to form a cream colored reaction mixture. The creamy reaction mixture was agitated at about 20°C for about 6 hours. The reaction 10 solids were isolated and rinsed with ether. The combined ether fractions were concentrated under reduced pressure to afford N-(2-bromoacetyl)-morpholine (3.37 g) 15 as a reddish oil, which was used without further purification.

A solution of the N-(2-bromoacetyl)-morpholine (2.09 g, 10 mmol) in acetone (5 mL) was introduced in a drop wise manner into a mixture of 3,7-Dihydroxy-naphthalene-2- 20 carboxylic acid benzyl ester (2.69 g, 9.1 mmol) and K₂CO₃ (1.39 g, 10.1 mmol) in 15 mL of acetone. The combined mixture was heated to reflux for about 12 hours, at which time another 0.2 g (1.0 mmol) of N-(2-bromoacetyl)-morpholine and 0.24 g of K₂CO₃ (1.7 mmol) were added and the heating continued for an additional 3 hours. The mixture was cooled to ambient temperature, diluted with AcOEt, washed with

water and satd. NaCl, dried (Na₂SO₄) and concentrated under reduced pressure to yield an oily residue. The oily residue was purified by chromatography (silica) using a gradient elution employing 50 to 80% AcOEt in hexanes. The title compound was obtained as a yellow foam (1.06 g, 28%). ¹H-NMR (d₆-DMSO) δ (ppm): 10.08 (s, 1H), 8.31 (s, 1H), 7.687 (d, 1H, J = 9.2 Hz), 7.50 (d, 2H, J = 7.0 Hz), 7.44-7.37 (m, 3H), 7.29 (s, 1H), 7.23 (d, 2H, J = 8.8 Hz), 5.41 (s, 2H), 4.85 (s, 2H), 3.59-3.44 (m, 8H).

3-Acetoxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid chloride


10 3-Hydroxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid benzyl ester (1.06 g, 2.5 mmol) was hydrogenated at atmospheric pressure in 10 mL of tetrahydrofuran over 10% Pd-C (wet) for 2 hours. The catalyst was removed by filtration, and solvent was removed under reduced pressure to yield the carboxylic acid as a yellow solid (0.77 g, 93%) was used without further purification.

15 3-Hydroxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid (from above) was moistened with 3 mL of acetic anhydride and 2 drops of conc. H₂SO₄. The resulting heterogeneous mixture was agitated for 20 min, and the undissolved solids were dissolved by adding 1 mL glacial AcOH. The resulting reaction mixture was concentrated under reduced pressure, the concentrated reaction 20 mixture was diluted with AcOEt (250 mL), dried (Na₂SO₄) and concentrated under reduced pressure to afford the 3-Acetoxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid as a pale yellow oil, which was taken directly onto the next step.

Oxalyl chloride (0.25 mL, 2.8 mmol) was added drop wise to a mixture of the 3-Acetoxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid (from above), 5 mL of 1,4-dioxane and 0.1 mL of N,N-dimethylformamide. The resulting solution was agitated for about 1 hour. The agitated reaction mixture was concentrated under reduced pressure to yield the acyl chloride which was used without further purification coupling with the appropriate aniline derivative to yield the compound of Example 167.

TABLE-III below lists compounds wherein R⁷ is a guanidinyl group (NH-C(=NH)NH₂) and X₁ represents a nitrogen atom.

TABLE-III



Ex.	R ²	R ³	R ⁴	R ⁵
200	H	H	H	H
201	H			H
202	H	OC_2H_5	H	H
203	H	H	CH_3	H

Ex.	R ²	R ³	R ⁴	R ⁵
204	H	H	H	OH
205	I	H	CH ₃	H
206	H	CH ₃	H	H
207	H			H
208	H			H
209	H			H
210	H			H
211	NH ₂			H
212	OH			H

Ex.	R ²	R ³	R ⁴	R ⁵
213	H			H
214	SO ₃ H			H
215	H			H
216	H			H

Listed below is the proton NMR (^1H NMR) and Mass spectral data for compounds listed in TABLE-III.

Ex. 200

^1H NMR (DMSO- d_6) δ : 11.67 (s, 1H), 11.26 (s, 1H), 10.59 (s, 1H), 8.71 (d, 1H, J = 2.48), 8.21-8.17 (m, 3H), 7.95 (dd, 1H, J = 1.24, 8.17), 7.45 (td, 1H, J = 1.73, 8.91, 8.42), 7.11 (d, 1H, J = 8.91), 7.00 (d, 1H, J = 8.91), 6.96 (d, 1H, J = 7.43).

Mass Spec (M+1) = 271.8

Ex. 201 : 3-hydroxy-naphthalene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide
10

This compound was prepared by reacting 3-acetoxy-naphthalene-2-carboxylic acid chloride (alternatively named as acetic acid 3-chlorocarbonyl-naphthalen-2-yl ester) with N-(5-Amino-pyridin-2-yl)-guanidine hydrochloride. N-(5-Amino-pyridin-2-yl)-guanidine hydrochloride was prepared as described below.

15

N-(5-Amino-pyridin-2-yl)-guanidine hydrochloride

The first step comprised synthesis of N-(5-nitro-pyridin-2-yl)-guanidine using the procedure of Carbon and Tabata described in *J. Org. Chem* (1962) 2504-7.

^1H NMR (DMSO- d_6) δ : 12.23 (s, 1H), 9.12 (d, 1H, J = 2.97 Hz), 8.62 (dd, 1H, J = 2.97, 8.91 Hz), 8.49 (s, 2H), 7.26 (d, 1H, 8.91 Hz).

The second step comprised synthesizing N-(5-amino-pyridin-2-yl)-guanidine hydrochloride by preparing a mixture of N-(5-nitro-pyridin-2-yl)-guanidine hydrochloride (15.82 g; 73 mmol) and 10% Pd/C (100mg) and methanol (1L). This mixture then was agitated in an atmosphere of hydrogen for 2 hours. The agitated

mixture was filtered and the filtrate concentrated to yield N-(5-amino-pyridin-2-yl)-guanidine hydrochloride (13.4 g) as a yellow solid.

¹H NMR (DMSO-d₆) δ : 10.88 (s, 1H), 8.01 (s, 2H), 7.65 (d, 1H, J = 2.72 Hz), 7.09 (dd, 1H, J = 2.72, 8.66 Hz), 6.80 (d, 1H, J = 8.66 Hz), 5.29 (d, 2H, J = 4.70 Hz).

5

3-acetoxy-naphthalene-2-carboxylic acid chloride (alternatively named as acetic acid 3-chlorocarbonyl-naphthalen-2-yl ester)

The acid chloride, above, was prepared by treating a mixture of 2-acetoxy-3-naphthoic acid (5 g, 22 mmol), EtOAc (80 ml) and DMF (3 drops) with oxalyl chloride (2.8 ml, 1.5 eq). The resulting reaction mixture was agitated for 0.5 h and the agitated mixture was concentrated *in vacuo* to a yield 3-acetoxy-naphthalene-2-carboxylic acid chloride as a yellow solid.

EX.: 201 3-hydroxy-naphthalene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide

15 The above acid chloride (1 eq.) was mixed with DMA (20 ml) and N-(5-amino-pyridin-2-yl)-guanidine hydrochloride (5.33 g, 1.3 eq) and the resulting mixture was agitated for 8-16 hours under an atmosphere of nitrogen. The agitated reaction mixture then was mixed with conc. ammonium hydroxide (150 ml) to form a yellow precipitate. The precipitate was isolated, dried and mixed with 1 M HCl . The 20 mixture was agitated for 2 h, the resulting solids were isolated and dried to yield 3-hydroxy-naphthalene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide (6.4 g, 78%) as a pale yellow solid.

¹H NMR (DMSO-d₆) δ: 11.24 (s, 1H), 11.19 (s, 1H), 10.77 (s, 1H), 8.77 (d, 1H, J = 2.23), 8.49 (s, 1H), 8.24 (dd, 1H, J = 2.48, 8.91), 8.21 (s, 1H), 7.93 (d, 1H, J = 7.92),

7.77 (d, 1H, J = 8.42), 7.52 (t, J = 6.93, 7.18), 7.39-7.34 (m, 2H), 7.13 (d, 1H, J = 8.91).

Mass Spec (M+1) = 321.8

Ex. 202

5 ^1H NMR (DMSO- d_6) δ 8.60 (s, 1H), 8.06 (d, 1H, J = 8.66), 7.73 (d, 1H, J = 8.66), 6.97 (d, 1H, J = 8.91), 6.14-6.10 (m, 2H), 3.95 (q, 2H, J = 6.68), 1.28 (t, 3H, J = 6.68).

Mass Spec (M+1) = 315.8

Ex. 203

10 ^1H NMR (DMSO- d_6) δ 8.57 (s, 1H), 8.02 (d, 1H, J = 8.91), 7.65 (s, 1H), 7.07 (d, 1H, J = 8.17), 6.92 (d, 1H, J = 8.91), 6.69 (d, 1H, J = 8.42), 2.20 (s, 3H).

Mass Spec (M+1) = 285.8

Ex. 205

15 ^1H NMR (DMSO- d_6) δ 11.37 (s, 1H), 10.86 (s, 1H), 8.67 (d, 1H, J = 2.23), 8.23-8.16 (m, 3H), 7.98 (s, 1H), 7.84 (d, 1H, J = 1.73), 7.13 (d, 1H, J = 8.91), 2.29 (s, 3H).

15 Mass Spec = 411.7

Ex. 206

15 ^1H NMR (DMSO- d_6) δ 8.69 (d, 1H, J = 2.72), 8.17 (dd, 1H, J = 2.72, 8.91), 7.87 (d, 1H, J = 7.92), 7.09 (d, 1H, J = 8.66), 6.79 (s, 1H), 6.76 (d, 1H, J = 8.42), 2.29 (s, 3H).

20 Mass Spec (M+1) = 285.9

UTILITY

Proteases play a significant role in the progression of Cancer. Compounds of the present invention are useful as protease inhibitors. Their inhibitory activity

includes inhibition of urokinase (uPA) which has been postulated to have therapeutic value in treating cancers such as lung cancer, breast cancer, pancreatic cancer, colon cancer, ovarian cancer, bone cancer and the like.

The compounds of the present invention are also useful as anticoagulants for
5 the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example unstable angina, first or recurrent ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, kidney 10 embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to the inhibition of Factor Xa (FXa), Factor VIIa (FVIIa), and thrombin.

Some of the compounds of the present invention show selectivity between uPA and FXa, with respect to their inhibitory properties. The effectiveness of 15 compounds of the present invention as inhibitors of Urokinase and Factor Xa is determined by using synthetic substrates and purified Urokinase and purified human Factor Xa respectively.

The rates of hydrolysis by the chromogenic substrates were measured both in the absence and presence of compounds of the present invention. Hydrolysis of the 20 substrates result in the release of a chromogenic moiety, which is monitored spectrophotometrically by measuring the increase in absorbance at 405 nano meter (nm). A decrease in the rate of absorbance change at 405 nm in the presence of a inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as the inhibitory constant, K_i app. Factor Xa determinations were made in

50 mM Tris buffer, pH 7.5, containing 1M NaCl, 5 mM CaCl₂, 0.05% Tween-20, and 1.5 mM EDTA. Values of Ki app. were determined by allowing 2-3 nM human Factor Xa (Haematologic Technologies, VT, USA) to react with the substrate (1 mM) in the presence of an inhibitor. Hydrolysis of the chromogenic substrate is followed spectrophotometrically at 405 nm for five minutes. The enzyme assay routinely yielded linear progression curves under these conditions. Initial velocity measurements calculated from the progress curves by a kinetic analysis program (Batch Ki; Peter Kuzmic, BioKin, Ltd., Madison, WI) were used to determine Ki app.

10 Urokinase inhibition determinations were made in 50 mM Tris (pH 7.5), 150 mM NaCl, 0.05% Tween-20, 0.002% antifoam, and 1 mM EDTA. human Urokinase (from American Diagnostica, CT, USA). Values of Ki app. were determined by allowing 20 nM human Urokinase to react with the Pefachrome substrate (0.3 mM, Centerchem, CT, USA) in the presence of an inhibitor. Hydrolysis of the chromogenic substrate is followed spectrophotometrically at 405 nm for five minutes. The enzyme assay routinely yielded linear progression curves under these conditions. Initial velocity measurements calculated from the progress curves by a kinetic analysis program (Batch Ki; Peter Kuzmic, BioKin, Ltd., Madison, WI) were used to determine Ki app.

15 Table IV lists inhibition constants (Ki app.) for representative compounds of the present invention. These values are for uPA and FXa.

TABLE-IV

Ex.	uPA	FXa
	Ki μ M	Ki μ M
1	0.16	0.88
5	0.29	0.84
24	2.9	34
201	0.326	130
205	5.5	290

5

Definitions

The compounds of the present invention may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of materials. Many geometric isomers of olefins, C=N double bonds, and the like can be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure (representing a compound of Formula I) are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

As used herein, the following terms and abbreviations have the following meaning, unless indicated otherwise.

The term "prodrug" is intended to represent covalently bonded carriers which are capable of releasing the active ingredient of Formula I, when the prodrug is 5 administered to a mammalian subject. Release of the active ingredient occurs *in vivo*. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or *in vivo*. Prodrugs of compounds of Formula I include 10 compounds wherein a hydroxy, amidino, guanidino, amino, carboxylic or a similar group is modified.

"Pharmaceutically acceptable salts" is as understood by one skilled in the art. Thus a pharmaceutically acceptable salt includes acid or base salts of compounds of Formula I. Illustrative examples of pharmaceutically acceptable salts are mineral 15 acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in 20 *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference.

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For

example, the phrase "optionally is substituted with one to three substituents" means that the group referred to may or may not be substituted in order to fall within the scope of the invention. Thus the term "optionally substituted" is intended to mean that any one or more hydrogens on a designated atom can be replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.

When the substituent is keto (=O) then 2 hydrogens on the atom are replaced. There are one to three "optional substituents", unless otherwise indicated, and these substituents are independently selected from a group consisting of H; N(R¹⁰)₂; NO₂; halogen; aryl; O-C₅₋₁₀ cyclo alkyl substituted with R¹⁰; guanidino; urea; thio urea; amidino; para or meta phenoxy; piperidin-4-yloxy; 4-amino-cyclohexyloxy; 1-(1-Imino-ethyl)-piperidin-4-yloxy; 1-(1-Imino-ethyl)-pyrrolidin-3-yloxy; 2-Amino-3-methyl-butyryl; 4-Acetimidoylamino-cyclohexyloxy; 1-(1-Imino-ethyl)-pyrrolidin-2-ylmethoxy; 2-(2-Hydroxycarbonimidoyl-pyridin-3-yloxy)-ethoxy; 3,4-Dicyano-phenoxy; SC₁₋₄ alkyl, S-aryl, O-C₁₋₄ alkyl, COOR¹⁰, OR¹⁰, C(O)-pyrrolidine; C(O)CH(NH₂)CH₂OH; C(O)CH(NH₂)CH₂Ph; C(O)CH(NH₂)CH₂COOH; O-pyrrolidine; C(O)-(CH₂)₁₋₃-imidazole; SO₂-N(alkyl)₂; C(=N)-C₃; O-piperidine; 2-aminothiazol-5-ylmethoxy; O-CH₂-COOH; pyrrolidine-2-ylmethoxy; 2,4,6-triamino pyrimidin-5-ylmethoxy; NH-SO₂-alkyl; NHC_{1-C} alkyl; N(C_{1-C}4)₂ alkyl; CF₃; C₂₋₁₀ alkenyl and C₁₋₁₀ alkyl.

The term "alkyl", as used herein, is intended to include branched and straight chain saturated aliphatic hydrocarbon groups having from 1 to 14 or the specified number of carbon atoms, illustrative examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, and

n-hexyl. "Alkenyl" is intended to include a branched or straight chain hydrocarbon group having one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like. The term "alkelene" represents an alkyl group, as defined above, except that it has at least one center of unsaturation, i.e., a double bond. Illustrative examples are butene, propene, and pentene. The term "cycloalkyl", "cycloalkyl ring", "cycloalkyl radical" or "cyclic hydrocarbon" indicates a saturated or partially unsaturated three to fourteen carbon monocyclic or bicyclic hydrocarbon moiety which is optionally substituted with an alkyl group. Illustrative examples include cyclo propyl, cyclo hexyl, cyclo pentyl, and cyclo butyl. The term "alkoxy" as used herein represents -OC₁₋₆ alkyl.

The terms "Ar" and "aryl", as used herein, are intended to represent a stable substituted or unsubstituted (collectively also referred to as 'optionally substituted') six to fourteen membered mono-, bi- or tri-cyclic hydrocarbon radical comprising carbon and hydrogen atoms. Illustrative examples are phenyl (Ph), naphthyl, anthracyl groups, and piperanyl. It is also intended that the terms "carbocycle" and "carbocyclic" include "Ar", "aryl" as well as "cyclo alkyl" groups, which are defined above. "Halogen" or "halo", as used herein, represents Cl, Br, F or I.


The term "heteroaryl" is intended to represent a stable 5 to 10 membered aryl group ("aryl" as defined above), wherein one or more of the carbon atoms is replaced by a hetero atom selected from N, O, and S. The hetero atoms can exist in their chemically allowed oxidation states. Thus a Sulfur (S) atom can exist as a sulfide, sulfoxide, or sulfone. Preferred heteroaryl groups are six membered ring systems comprising not more than 2 hetero atoms. Illustrative examples of preferred heteroaryl groups are thienyl, N-substituted succinimide, 3-(alkyl amino)-5,5-

dialkyl-2-cyclohexen-1-one, methyl pyridyl, alkyl theophylline, furyl, pyrrolyl, indolyl, pyrimidinyl, isoxazolyl, purinyl, imidazolyl, pyridyl, pyrazolyl, quinolyl, and pyrazinyl. The term "heterocycloalkyl" means a stable cyclo alkyl group containing from 5 to 14 carbon atoms wherein one or more of the carbon atoms is replaced by a hetero atom chosen from N, O and S. The hetero atoms can exist in their chemically allowed oxidation states. Thus Sulfur (S) can exist as a sulfide, sulfoxide, or sulfone. The heterocycloalkyl group can be completely saturated or partially unsaturated. Illustrative examples are piperidine, 1,4-dioxane, and morpholine.

As used herein the terms "heterocyclyl", "heterocyclic" and/or "het" are intended to represent a stable 5- to 7- membered monocyclic or 7- to 10- membered bicyclic heterocyclic ring which is saturated, partially unsaturated, or unsaturated (aromatic), which consists of carbon atoms and from one to 4 hetero atoms independently selected from a group consisting of N, O and S. The nitrogen and the sulfur hetero atoms can exist in their respective oxidized states. The heterocyclic ring may be attached to its pendent group at any hetero atom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on a carbon or a nitrogen atom if the resulting compound is stable. The nitrogen in the heterocycle can exist in its quaternized form. It is preferred that when the total number of hetero atoms in the heterocycle exceeds 1, then the hetero atoms are not adjacent to one another. It is understood that the terms "heterocyclyl", "heterocyclic", and "het" include the terms "heteroaryl", "heterocycloalkyl" and "bicyclic heterocyclic ring structure" as described above.

Preferred "heterocyclyl", "heterocyclic" and/or "het" groups are selected from
1-(2-Hydroxymethyl-pyrrolidin-1-yl)-2,3-dimethyl-butan-1-one, 3-Pyridin-2-yl-
propan-1-ol, N-(2,3-Dimethoxy-benzyl)-2-hydroxy-acetamide, 1-Methyl-2-m-tolyl-
1H-benzoimidazole-5-carboxamidine, 2-Methyl-3,4,6,7-tetrahydro-imidazo[4,5-
5 c]pyridine-5-carboxamidine, 2-Amino-3-hydroxy-1-(2-methyl-3,4,6,7-tetrahydro-
imidazo[4,5-c]pyridin-5-yl)-propan-1-one, 2-Amino-1-(2-methyl-3,4,6,7-tetrahydro-
imidazo[4,5-c]pyridin-5-yl)-ethane, 2-Methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-
c]pyridine, N-o-Tolyl-methanesulfonamide, 2-Methyl-benzothiazole, 3-Amino-1-(2-
hydroxymethyl-pyrrolidin-1-yl)-propan-1-one, 2-Hydroxy-1-(2-hydroxymethyl-
10 pyrrolidin-1-yl)-ethanone, 2-(2-Hydroxy-ethyl)-indan-1,3-dione, 5-Fluoro-2-
methyl-1H-benzoimidazole, 2-Methyl-1H-imidazo[4,5-c]pyridine, 2-Hydroxy-N-(2-
morpholin-4-yl-ethyl)-acetamide, 2-Methyl-1H-imidazo[4,5-b]pyridine, 2-Amino-1-
15 (3-methyl-piperidin-1-yl)-ethanone, 2-Methyl-1H-benzoimidazol-4-ol, 2-Pyridin-2-
yl-ethanol, N-(3-Hydroxy-propyl)-2-phenyl-acetamide, N-(3-Hydroxy-propyl)-3-
phenyl-propionamide, N-(3-Hydroxy-propyl)-benzamide, N-(2-Hydroxy-ethyl)-2-
phenyl-acetamide, (4-Hydroxy-butyl)-carbamic acid tert-butyl ester, (2-Hydroxy-
ethyl)-carbamic acid benzyl ester, (4-Hydroxy-piperidin-1-yl)-phenyl-methanone,
4-Bromo-2-methoxy-benzylamine, 3-Methoxy-5-trifluoromethyl-benzylamine, N-
15 (3,5-Dimethoxy-benzyl)-acetamide, 2-Methyl-1H-benzoimidazole-5-
carboxamidine, and 2-Hydroxy-N-naphthalen-1-yl-acetamide.

The following structural representations further illustrate the term "het":



wherein G_1 and G_2 independently at each occurrence represent $S(O)_{0-2}$, NH , $N-R^{24}$, O , CR^{10} , or CHR^{10} ; J_1 , J_2 , J_3 , and J_4 independently represent CR^{10} or N , wherein at least two of J_1 , J_2 , J_3 , and J_4 represent CH ; K_1 , K_2 , K_3 and K_4 independently represent $-NHR^{10}$, $-NHR^{24}$, $-CHR^{10}$, $-CH-C(=NH)-NH_2$, or $N-C(=NH)-NH_2$ wherein at least two of K_1 , K_2 , K_3 and K_4 represent CH_2 ; M_1 , M_2 , M_3 and M_4 independently represent $-NHR^{10}$, $-NHR^{24}$, $-CHR^{10}$, $-CH-C(=NH)-NH_2$, or $N-C(=NH)-NH_2$, wherein at least two of M_1 , M_2 , M_3 and M_4 represent CH or CH_2 ; and R^{25} represents H , halogen, $-C_{1-6}$ alkyl, $-NO_2$, NHR^{10} , $NH-SO_2-R^{10}$, $-OH$, C_{1-6} alkoxy, amidino, guanidino, $-COOR^{10}$, or $-CONHR^{10}$. The variables R^{10} and R^{24} are as defined earlier. The dashed lines indicate optional unsaturation without violating the valency rules.

The term "basic group" as used under R^7 and R^8 , defined earlier, is intended to represent amidino, guanidino, $-C(=NH)N(R^{10})_2$, 2-imidazoline, $-N$ -amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine. The compounds of the present invention were named using the "Autonom", a Beilstein Commander 2.1 Application, distributed by Beilstein.

The term "acylatable group" as used herein represents a group which is capable of reacting with an acylating group to form an amido group. Illustrative examples of acylatable groups are primary or secondary amino, guanidino and amidino.

5 The term "acylating agent" as used herein represents a chemical agent which is capable of reacting with an acylatable group to form an amido group. Illustrative examples of an acylating agent are acid chloride and *N*-methylpyrrolidone.

10 The term "acetamide" as used herein represents a reagent that comprises an acetamide group. Illustrative examples of an acetamide are alkyl acetamide, dialkyl acetamide, dimethyl acetamide, dialkyl propionamide, and diethyl acetamide. The acetamide functions as a solvent and a base in the process of the present invention.

15 The term "natural amino acid", as used herein is intended to represent the twenty naturally occurring amino acids in their 'L' form, which are sometimes also referred as 'common amino acids', a list of which can be found in *Biochemistry*, Harper & Row Publishers, Inc. (1983). The term "unnatural amino acid", as used herein, is intended to represent the 'D' form of the twenty naturally occurring amino acids described above. It is further understood that the term unnatural amino acid includes homologues of the natural amino acids, and synthetically modified form of the natural amino acids. The synthetically modified forms include amino acids 20 having alkylene chains shortened or lengthened by up to two carbon atoms, amino acids comprising optionally substituted aryl groups, and amino acids comprised halogenated groups, preferably halogenated alkyl and aryl groups.

The term "natural amino acid side chain" is intended to represent a natural amino acid ("natural amino acid" as defined above) wherein a keto (C=O) group


replaces the carboxylic acid group in the amino acid. Thus, for example, an alanine side chain is C(=O)-CH(NH₂)-CH₃; a valine side chain is C(=O)-CH(NH₂)-CH(CH₃)₂; and a cysteine side chain is C(=O)-CH(NH₂)-CH₂-SH. The term "unnatural amino acid side chain" is intended to represent an unnatural amino acid ("unnatural amino acid" as defined above) wherein a keto (C=O) group replaces the carboxylic acid group forming unnatural amino acid side chains similar to ones illustrated under the definition of "natural amino acid side chain" above.

It thus follows that a "N-natural amino acid side chain" substituent and "N-unnatural amino acid side chain" substituent, which can represent Q, Q¹, Q², Q³, L¹, L², L³ and L⁴, is a group wherein the nitrogen atom (N) is the annular ring atom substituted with a natural or unnatural amino acid side chain (natural or unnatural amino acid side chain is a defined above). The point of attachment between the nitrogen atom and the natural or unnatural amino acid side chain is at the keto (C=O) group of the respective amino acids. Thus a N-natural amino acid, i.e., N-cysteine, is N-C(=O)-CH(NH₂)-CH₂-SH.

CLAIMS:

1. A compound of Formula I:

5




Formula I

its prodrug form or pharmaceutically acceptable salts thereof, wherein:

10 R^1 represents OH, COOH, COO-C_{1-4} alkyl, $\text{CH}_2\text{OR}^{10}$, $\text{SO}_2\text{-OH}$, $\text{O-SO}_2\text{-OH}$, $\text{O-SO}_2\text{-OC}_{1-4}$ alkyl, OP(O)(OH)_2 , or $\text{OPO}_3\text{C}_{1-4}$ alkyl;


R^2 , R^3 , R^4 , and R^5 independently at each occurrence represent H, SH, OR^{10} , halogen, COOR^{10} , $\text{CONR}^{11}\text{R}^{12}$, optionally substituted aryl, optionally substituted heterocyclyl, C_{4-14} cycloalkyl- C_{1-4} alkyl, C_{1-4} alkyl aryl, optionally substituted C_{1-14} straight chain, branched or cyclo alkyl, $\text{NR}^{10}\text{R}^{24}$, $(\text{CH}_2)_{1-4}\text{-NR}^{33}\text{R}^{34}$, $(\text{CH}_2)_{1-4}\text{-COOR}^{33}$, O-(CH_2)₁₋₃-CO-het, O-(CH_2)₁₋₂-NH-CO-aryl, O-(CH_2)₀₋₂-NR¹⁰-CO-NR¹⁰R³³, O-(CH_2)₀₋₂-C(O)-NR³³R³⁴, O-(CH_2)₁₋₄-COOR¹⁰, O-(CH_2)₁₋₃-het-R³², O-optionally substituted cycloalkyl, O-(CH_2)₁₋₄-NR¹⁰-COO-t-butyl, O-(CH_2)₁₋₄-NR¹⁰R³³, O-(CH_2)₁₋₄-NR¹⁰-C(O)-C₀₋₃-alkyl-optionally substituted aryl, O-(CH_2)₀₋₆

optionally substituted aryl, $(CH_2)_{1-4}-NH-C(O)O-(CH_2)_{1-4}-PhR^{13}R^{14}$, NO_2 , $O-(CH_2)_{0-4}-C(O)-NH$ -tetrahydro carboline, SO_3H , $CH(OH)COOR^{10}$, $NR^{10}R^{28}$, $O-(CH_2)_{1-3}$ -optionally substituted het, CH_2COOCH_3 , $CH=CH-COOCH_3$,




5

alternatively R^2 and R^3 , R^3 and R^4 , or R^4 and R^5 taken together form



10 R^6 , R^9 and R^{53} independently at each occurrence represents H, halogen, cyano, C_{1-4} alkyl, C_{1-4} halogenated alkyl, NO_2 , O -aryl or OR^{11} ;
alternatively R^6 and R^{53} taken together form



R^7 and R^8 independently at each occurrence represent OH, CF₃, H, COOH, NO₂, C₁₋₄

alkyl, OC₁₋₄ alkyl, or O-aryl, halogen, cyano, or a basic group selected from guanidino, NH(CH=NH)NH₂, C(=NH)N(R¹⁰)₂, C(=NH)-NH-NH₂, C(=O)N(R¹⁰)₂, 2-

5 imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, C(O)CH₂NH₂, C(O)NHCH₂CN, NHCH₂CN, and thiazolidin-3-yl-methylideneamine; with the proviso that only one of R^7 and R^8 represent a basic group;


R^{10} independently at each occurrence represents H, (CH₂)₀₋₂-aryl, C₁₋₄ halo alkyl, or

10 C₁₋₁₄ straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R^{10} groups, the atom along with the R^{10} groups can form a five to 10 membered ring structure;

X₁, X₂, X₃ and X₄ independently at each occurrence represent a carbon or a nitrogen atom;

15 R¹¹ and R¹² independently at each occurrence represent H or C₁₋₄ alkyl;

R^{13} represents H, OH, OC₁₋₄ alkyl, OAr, OC₅₋₁₀ cycloalkyl, OCH₂CN, O(CH₂)₁₋₂NH₂, OCH₂COOH, OCH₂COO-C₁₋₄ alkyl or



R^{20} represents H or OH;

R^{24} represents R^{10} , $(CH_2)_{1-4}$ -optionally substituted aryl, $(CH_2)_{0-4}OR^{10}$, $CO-(CH_2)_{1-2}-$

$N(R^{10})_2$, $CO(CH_2)_{1-4}-OR^{10}$, $(CH_2)_{1-4}-COOR^{10}$, $(CH_2)_{0-4}N(R^{10})_2$, SO_2R^{10} , COR^{10} ,

$CON(R^{10})_2$, $(CH_2)_{0-4}$ -aryl-COOR¹⁰, $(CH_2)_{0-4}$ -aryl-N(R¹⁰)₂, or $(CH_2)_{1-4}$ -het-aryl;

5 R^{28} represents $(CH_2)_{1-2}Ph-O-(CH_2)_{0-2}$ -het-R³⁰, C(O)-het, $CH_2-Ph-CH_2$ -het-(R³⁰)₁₋₃;

$(CH_2)_{1-4}$ -cyclohexyl-R³¹, $CH_2-Ph-O-Ph-(R^{30})_{1-2}$, $CH_2-(CH_2OH)$ -het-R³⁰, $CH_2-Ph-O-$

cycloalkyl-R³¹, CH_2 -het-C(O)-CH₂-het-R³⁰, or $CH_2-Ph-O-(CH_2)-O$ -het-R³⁰;

R^{30} represents $SO_2N(R^{10})_2$, H, NHOH, amidino, or C(=NH)CH₃;

R^{31} represents R^{30} , amino-amidino, NH-C(=NH)CH₃ or R^{10} ;

10 R^{32} represents H, C(O)-CH₂-NH₂, or C(O)-CH(CH(CH₃)₂)-NH₂;

R^{33} and R^{34} independently at each occurrence represent R^{10} , $(CH_2)_{0-4}Ar$, optionally


substituted aryl, $(CH_2)_{0-4}$ optionally substituted heteroaryl, $(CH_2)_{1-4}CN$, $(CH_2)_{1-4}-$

$N(R^{10})_2$, $(CH_2)_{1-4}OH$, $(CH_2)_{1-4}SO_2-N(R^{10})_2$;

alternatively, R^{33} and R^{34} along with the nitrogen atom that they are attached to

15 forms a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-

Dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



20 R^{35} represents R^{10} , SO_2-R^{10} , COR^{10} , or $CONHR^{10}$;

E represents a bond, $S(O)_{0-2}$, O or NR^{10} ;

Q, Q¹, Q², Q³, L¹, L², L³ and L⁴ independently at each occurrence represent N-natural or unnatural amino acid side chain, CHR¹⁰, O, NH, S(O)₀₋₂, N-C(O)-NHR¹⁰, SO₂-N(R¹⁰)₂, N-C(O)-NH-(CH₂)₁₋₄-R²⁶, NR¹⁰, N-heteroaryl, N-C(=NH)-NHR¹⁰, or N-C(=NH)C₁₋₄ alkyl;

5 R²⁶ represents OH, NH₂, or SH;

R⁵¹ and R⁵² independently represent COOH, CH₂OH, CH₂COOH, COOR, CH₂COOR, alkyl or CO-NH₂; alternatively

R⁵¹ and R⁵² taken together represent =O, =S, =CH₂ or =NR¹⁰;

R⁵³ represents H, halogen, cyano, C₁₋₄ alkyl, C₁₋₄ halogenated alkyl, NO₂, O-aryl or

10 OR¹¹;

with the proviso that at least two of X₁, X₂, X₃ and X₄ represent a carbon atom, and when any of X₁, X₂, X₃ and X₄ represent a nitrogen atom the corresponding substituent does not exist.

2. A compound of Claim 1 wherein

15 R¹ represents OH or COOH;

R²⁰ represents H;


R⁵¹ and R⁵² taken together form =O; and

X₁, X₂, X₃, and X₄ represent C.

3. A compound of Claim 2 wherein:

20 R² represents halo, H, NH-CO-Ph, i-propyl, OH, OCH₃, OC₂H₅, CH(OH)COOH, O-I-propyl, SO₃H, NH₂, CH(OH)COOC₁₋₂ alkyl, CH₃, NO₂ or Ph;


R³ represents H, OH, NH₂ OC₁₋₄ alkyl, C₁₋₄ alkyl, NHCH₃, O-(CH₂)₁₋₃-OCO-C₁₋₂ alkyl, NH-C(O)C₁₋₂ alkyl, O-(CH₂)₁₋₂-CO-NH₂, Ph, NHCOCF₃, N=CH-N(CH₃)₂, O-CH₂-CO-NH-(CH₂)₁₋₃-Ph,



R^4 represents H, C₁₋₄ alkyl, halogen, *i*-propyl, OH, NH₂ 3-nitro-phen-1-yl, NH-CO-CH₃, CH₂-NH-(CH₂)₃-Ph, 2,4-difluoro-phen-1-yl, NHCOCF₃, benzo[1,3]dioxol-5-yl, 4-Carbamimidoyl-phenylazo, 3-Hydroxy-4-carboxyl-phenylsulfanyl; 1,3-Dioxo-5-indan-2-yl, or toluene-4-sulfonylamino;

R^5 represents H or OH;

alternatively, R^2 and R^3 , R^3 and R^4 , or R^4 and R^5 can be taken together to form



10

R^6 represents H;

R^7 represents C(=NH)-NH₂ or NH-C(=NH)-NH₂;

R^8 represents H or halogen; and

R^9 represents H.

15


4. A compound of claim 3 wherein

R^2 represents halo, H, NH-CO-Ph, *i*-propyl, OH, CH₃, or NO₂;


R^3 represents H, OH, NH₂, OC₁₋₂ alkyl, C₁₋₄ alkyl, O-(CH₂)₁₋₃-OCO-C₁₋₂ alkyl, NH-C(O)CH₃, O-CH₂-CO-NH₂, Ph, NHCOCF₃, N=CH-N(CH₃)₂, O-CH₂-CO-NH-(CH₂)₂-Ph;

R^4 represents H, CH₃, methoxy, halogen, *i*-propyl, 3-nitro-phen-1-yl, NHCOCF₃,
5 benzo[1,3]dioxol-5-yl, NHCOCH₃, 4-Carbamimidoyl-phenylazo, 3-Hydroxy-4-carboxyl-phenylsulfanyl or 1,3-Dioxo-indan-2-yl;

alternatively, R² and R³, R³ and R⁴, or R⁴ and R⁵ can be taken together to form



10 R¹³ represents C₁₋₂ alkyl, OH, O(CH₂)₁₋₂-NH₂, H, or




5. A compound of Claim 4 wherein

15 R³ represents H, OH, NH₂, OC₁₋₂ alkyl, C₁₋₄ alkyl, O-CH₂-OCO-CH₃, NH-C(O)CH₃, O-CH₂-CO-NH₂;

R⁴ represents H, CH₃, halogen, *i*-propyl, benzo[1,3]dioxol-5-yl, or 1,3-Dioxo-indan-2-yl;

alternatively, R² and R³, R³ and R⁴, or R⁴ and R⁵ can be taken together to form



6. A compound of Claim 5 wherein

5 R^2 represents H or halogen;


R^3 represents H, OH or NH_2 ;

R^4 represents H, CH_3 , halogen or benzo[1,3]dioxol-5-yl;

R^5 represents H; or

R^3 and R^4 or taken together to form

10



7. A pharmaceutical composition comprising a pharmaceutically acceptable

15 carrier and a therapeutically effective amount of (i) a compound; or (ii) a pharmaceutically acceptable salt of a compound of Claim 1.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of a compound of Claim 4.

9. A method for treating or preventing a thromboembolic disorder, comprising
5 administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 4 or a pharmaceutically acceptable salt thereof.

10. A compound of Claim 6, wherein the compound is selected from:

N-(4-Carbamimidoyl-phenyl)-2-hydroxy-3-iodo-5-methyl-benzamide;

3,5-Dibromo-N-(4-carbamimidoyl-phenyl)-2,4-dihydroxy-benzamide;

10 5-Bromo-N-(4-carbamimidoyl-phenyl)-2,4-dihydroxy-3-iodo-benzamide;

3-Hydroxy-naphthalene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide; and

3-Hydroxy-7-methoxy-naphthalene-2-carboxylic acid (4-guanidino-phenyl)-amide.

11. A compound of Claim 1 wherein

R¹ represents OH or COOH;

15 R²⁰ represents H;

R⁵¹ and R⁵² taken together form =O;


X₁ represents N; and

X₂, X₃, and X₄ represent C.

12. A compound of Claim 1 wherein

20 R² represents halo, H, NH-CO-Ph, *i*-propyl, OH, CH₃, NO₂ or Ph;


R³ represents H, OH, NH₂ OC₁₋₄ alkyl, C₁₋₄ alkyl, O-(CH₂)₁₋₃-OCO-C₁₋₂ alkyl, NH-C(O)C₁₋₂ alkyl, O-(CH₂)₁₋₂-CO-NH₂, Ph, NHCOCF₃, N=CH-N(CH₃)₂, O-CH₂-CO-NH-(CH₂)₁₋₃-Ph,



R⁴ represents H, C₁₋₄ alkyl, halogen, *i*-propyl, OH, NH₂ 3-nitro-phen-1-yl, NH-CO-CH₃, CH₂-NH-(CH₂)₃-Ph, 2,4-difluoro-phen-1-yl, NHCOCF₃, benzo[1,3]dioxol-5-yl, 4-Carbamimidoyl-phenylazo, 3-Hydroxy-4-carboxyl-phenylsulfanyl; 1,3-Dioxo-5-indan-2-yl, or toluene-4-sulfonylamino;

R⁵ represents H or OH;

alternatively, R² and R³, R³ and R⁴, or R⁴ and R⁵ can be taken together to form



10

R⁶ represents H;

R⁷ represents C(=NH)-NH₂ or NH-C(=NH)-NH₂;

R⁸ represents H or halogen; and

R⁹ represents H.


15 13. A compound of claim 12 wherein

R² represents halo, H, NH-CO-Ph, *i*-propyl, OH, CH₃, or NO₂;


R^3 represents H, OH, NH_2 , OC_{1-2} alkyl, C_{1-4} alkyl, $O-(CH_2)_{1-3}-OCO-C_{1-2}$ alkyl, $NH-C(O)CH_3$, $O-CH_2-CO-NH_2$, Ph, $NHCOCF_3$, $N=CH-N(CH_3)_2$, $O-CH_2-CO-NH-(CH_2)_2-Ph$;

R^4 represents H, CH_3 , methoxy, halogen, *i*-propyl, 3-nitro-phen-1-yl, $NHCOCF_3$,
5 benzo[1,3]dioxol-5-yl, $NHCOCH_3$, 4-Carbamimidoyl-phenylazo, 3-Hydroxy-4-carboxyl-phenylsulfanyl or 1,3-Dioxo-indan-2-yl;

alternatively, R^2 and R^3 , R^3 and R^4 , or R^4 and R^5 can be taken together to form



10 R^{13} represents C_{1-2} alkyl, OH, $O(CH_2)_{1-2}-NH_2$, H, or




14. A compound of Claim 13 wherein

R^3 represents H, OH, NH_2 , OC_{1-2} alkyl, C_{1-4} alkyl, $O-CH_2-OCO-CH_3$, $NH-C(O)CH_3$,
15 $O-CH_2-CO-NH_2$;

R^4 represents H, CH_3 , halogen, *i*-propyl, benzo[1,3]dioxol-5-yl, or 1,3-Dioxo-indan-2-yl;

alternatively, R^2 and R^3 , R^3 and R^4 , or R^4 and R^5 can be taken together to form



15. A compound of Claim 14 wherein


5 R² represents H or halogen;

R³ represents H, OH or NH₂;

R⁴ represents H, CH₃, halogen or benzo[1,3]dioxol-5-yl;

R⁵ represents H; and

10 R³ and R⁴ or taken together to form



16. A pharmaceutical composition comprising a pharmaceutically acceptable

15 carrier and a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of a compound of Claim 10.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 13 or a pharmaceutically acceptable salt thereof.
18. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 13 or a pharmaceutically acceptable salt thereof.
5
19. A method for treating cancer in mammals comprising administering a therapeutically effective amount of a compound according to Claim 13.
20. A process for selectively acylating an amino group, said process comprising treating a molecule comprising an amino group with an acylating agent in the presence of an acetamide to yield a compound with an acylated amino group.
10
21. A process of Claim 20 wherein the amino group is selectively acylated in the presence of another acylatable group.
22. A process of Claim 21 wherein the acylatable group is selected from an optionally substituted amino ketone, alkyl amidino, alkyl guanidino, C(=NH)NH-NH₂, aryl-(CH₂)₀₋₄-NHR¹⁰, amidino and guanidino.
15
23. A process of Claim 22 wherein the acylating agent comprises an acid halide group.
24. A process of Claim 23 wherein the acetamide is an alkyl or dialkyl acetamide.
25. A process of Claim 24 wherein the acetamide is selected from a group consisting of DMA, diethyl acetamide, dimethyl propionamide, diethyl propionamide and N-methylpyrrolidinone.
20
26. A process of Claim 25 wherein the process is carried out at a temperature ranging from about 25°C to about 50°C.

27. A process of Claim 26 wherein the acylating agent is a protected salicylic acid chloride selected from acetic acid 2-chlorocarbonyl-phenyl ester and 2-benzyloxybenzoyl chloride.

28. A method for treating or preventing a cancer related disorder, comprising
5 administering to a patient/ mammal in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

29. A method for treating or preventing a cancer related disorder, comprising administering to a patient/ mammal in need thereof a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt thereof.

10 30. A method for treating or preventing a cancer related disorder, comprising administering to a patient/ mammal in need thereof a therapeutically effective amount of a compound of Claim 12 or a pharmaceutically acceptable salt thereof.

31. A method for treating or preventing a cancer related disorder, comprising administering to a patient/ mammal in need thereof a therapeutically effective amount
15 of a compound of Claim 15 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/ 00/34211

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C257/18 C07C279/18 A61K31/155 A61P7/02 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Derwent Publications Ltd., London, GB; AN 1999-508614 XP002161780 "New amidino compound useful for treating..." & WO 99 41231 A (ONO PHARMACEUTICALS CO LTD.), 19 August 1999 (1999-08-19) abstract & DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RN 239457-45-5 and 239457-46-6, --- A	1,2,7,9, 11,18
A	WO 99 05096 A (ABBOTT LAB) 4 February 1999 (1999-02-04) the whole document ---	1-19, 28-31 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 March 2001

Date of mailing of the international search report

28-05-01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Janus, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 00/34211

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 576 343 A (NAGAHARA TAKAYASU ET AL) 19 November 1996 (1996-11-19) cited in the application the whole document ---	1-19, 28-31
A	EP 0 635 492 A (LILLY CO ELI) 25 January 1995 (1995-01-25) examples 39,40 ---	1-19, 28-31
A	EP 0 703 216 A (ONO PHARMACEUTICAL CO) 27 March 1996 (1996-03-27) tables 1,3,8,10 -----	1-19, 28-31

INTERNATIONAL SEARCH REPORT

International application No.
CT/US 00/34211

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9, 18, 19 and 28-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. Claims Nos.: 1-19 and 28-31 (all in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 - 19, 28 - 31

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00/34211

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-19 and 28-31 (all in part)

Present claims 1-6 and 10-15 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT is to be found, however, for only a very small proportion of the compounds claimed. The same applies to the compositions claimed in claims 7, 8, 16 and 17 and to the methods of claims 9, 18, 19 and 28-31. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds or formula I wherein R1 is OH, R51 and R52 together are =O, R20 is H, X, X2, X3 and X4 are C, R9 is H, and R7 is amidinyl or guanidinyl.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00/34211

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19, 28-31

Compounds of formula (I), their use in pharmaceutical compositions, and in the treatment of thromboembolic disorders and of cancer.

2. Claims: 20-27

Process for the acylation of an amino group.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/ 00/34211

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9941231	A	19-08-1999	AU 2300699 A EP 1078917 A	30-08-1999 28-02-2001
WO 9905096	A	04-02-1999	AU 8587498 A BG 103981 A CN 1265645 T EP 1000018 A NO 996578 A PL 339429 A SK 174899 A ZA 9806594 A	16-02-1999 30-11-2000 06-09-2000 17-05-2000 25-01-2000 18-12-2000 12-06-2000 27-01-1999
US 5576343	A	19-11-1996	AT 136293 T AU 666137 B AU 2747092 A CA 2081836 A CN 1072677 A,B CN 1168885 A CN 1168886 A,B CZ 284381 B DE 69209615 D DE 69209615 T DK 540051 T EP 0540051 A ES 2088073 T FI 924932 A GR 3019832 T HK 1002999 A HR 921147 B HR 921147 A HU 65890 A IL 103564 A JP 10291931 A JP 2879718 B JP 5208946 A KR 205152 B MX 9206295 A NO 302948 B NZ 244936 A PL 170312 B RU 2139851 C SK 327692 A US 5962695 A US 5620991 A US 5866577 A ZA 9208276 A	15-04-1996 01-02-1996 06-05-1993 01-05-1993 02-06-1993 31-12-1997 31-12-1997 11-11-1998 09-05-1996 09-01-1997 06-05-1996 05-05-1993 01-08-1996 01-05-1993 31-08-1996 30-09-1998 30-04-1999 31-10-1995 28-07-1994 06-12-1998 04-11-1998 05-04-1999 20-08-1993 01-07-1999 01-08-1993 11-05-1998 26-05-1995 29-11-1996 20-10-1999 13-04-1999 05-10-1999 15-04-1997 02-02-1999 06-05-1993
EP 0635492	A	25-01-1995	US 5618843 A AU 685807 B AU 6750094 A BR 9402916 A CA 2128348 A CN 1108248 A,B CN 1274723 A CZ 9401740 A FI 943478 A FI 20000648 A HU 70397 A	08-04-1997 29-01-1998 02-02-1995 11-04-1995 23-01-1995 13-09-1995 29-11-2000 13-09-1995 23-01-1995 20-03-2000 30-10-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/ 00/34211

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0635492	A	JP	8188564 A	23-07-1996
		NO	942734 A	23-01-1995
		NZ	264060 A	22-08-1997
		PL	304388 A	23-01-1995
		RU	2140907 C	10-11-1999
		US	6020362 A	01-02-2000
		US	5731324 A	24-03-1998
		US	6137002 A	24-10-2000
		ZA	9405251 A	18-01-1996
<hr/>		<hr/>		
EP 0703216	A 27-03-1996	AT	178589 T	15-04-1999
		CA	2158676 A	21-03-1996
		DE	69508875 D	12-05-1999
		DE	69508875 T	16-09-1999
		DK	703216 T	18-10-1999
		ES	2132535 T	16-08-1999
		GR	3030433 T	30-09-1999
		JP	8143529 A	04-06-1996
		KR	226619 B	15-10-1999
<hr/>		<hr/>		